Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis  by Alexander, Jessy J. et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1639 (2003) 169–176Administration of the soluble complement inhibitor, Crry-Ig, reduces
inflammation and aquaporin 4 expression in lupus cerebritis
Jessy J. Alexandera,*, Lihua Baoa, Alexander Jacoba, Damien M. Krausb,
V. Michael Holersb, Richard J. Quigga
aDepartment of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637, USA
bDepartment of Medicine, Division of Rheumatology, University of Colorado Health Sciences Center, Denver, CO 80262, USAReceived 24 January 2003; received in revised form 27 June 2003; accepted 19 September 2003Abstract
Changes in brain water and cerebral volume can lead to brain edema that may be one of the underlying causes of death in many neurological
diseases. Cerebral water content is regulated by aquaporin 4 (AQ4) present in astrocytic end feet and around blood vessels. In systemic lupus
erythematosus (SLE), magnetic resonance imaging (MRI) studies of the brain have demonstrated lesions with the prominent appearance of
edema. Activation of complement may play a significant role in the pathogenesis of lupus cerebritis by causing inflammation that can lead to
edema. In this study, the well-established MRL/lpr lupus mouse model was used to evaluate the role of complement in lupus cerebritis. IgG and
C1q colocalized in perivascular deposits indicating that the blood–brain barrier was compromised. Both RNA and protein expressions of AQ4
were significantly increased in brains of MRL/lpr mice. Chronic administration of the soluble complement inhibitor, Crry-Ig, reduced
inflammation as measured by decreased accumulation of IgG. In contrast to control MRL/lpr mice, AQ4 expression in complement inhibited
MRL/lpr mice was not changed relative to untreated congenic controls. These results illustrate that complement activation in brains of lupus
mice leads to enhanced AQ4 expression and inflammation. It is conceivable that increased AQ4 expression results in cerebral edema and hence
complement inhibition may provide a new therapeutic option in inflammatory cerebral disorders such as lupus cerebritis.
D 2003 Elsevier B.V. All rights reserved.Keywords: Crry-Ig; Inflammation; Aquaporin 4 expression; Lupus cerebitis1. Introduction
Brain water content and volume are tightly regulated to
assure the normal functioning of the central nervous system
(CNS). The brain is encased in the rigid cranium and is highly
sensitive to any increase in intracranial pressure. Alterations
in cerebral water homeostasis and distribution may lead to
neuronal and glial swelling known as cytotoxic brain edema,
due to accumulation of intracellular water. Cerebral edema
plays a significant role in the morbidity and death associated
with many common neurological disorders such as systemic
lupus erythematosus (SLE) and multiple sclerosis.
The complement cascade is involved in the development
of brain pathology in diseases such as SLE and injury [1].
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contributing to inflammation within the injured brain [2–5].
Staining for complement components C1q, C3b, C3d and the
membrane attack complex (MAC) were increased in resected
tissue from patients with intracranial hypertension [6,7].
These studies suggest that complement activation may play
an important role in the development of secondary brain
damage such as edema. This is substantiated by the studies in
which complement inhibition with N-acetylheparin and
complement depletion with cobra venom factor reduced
brain edema after experimental intracerebral hemorrhage [8].
Each member of the aquaporin (AQ) family has a unique
tissue distribution. In brain, AQ1 is present in the apical
plasma membranes of cells of the choroid plexus in the
ventricles, where it has been suggested to participate in the
secretion of cerebrospinal fluid. AQ4 is a highly conserved
water channel protein present in the plasma membranes of
ependymal cells and astrocytes. AQ4 was shown to have a
role in the formation of brain edema and brain water homeo-
stasis [9].
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of SLE. Transient hypodensities have been noted on com-
puterized tomography (CT) scans of SLE patients. Magnetic
resonance imaging (MRI) scans of SLE patients reveal
vasculitis, arterial spasm and increased vascular permeabil-
ity, all of which eventually can lead to cerebral edema [10].
Here we studied the well-established lupus mouse model
MRL/lpr. This strain is on the autoimmune MRL/MpJ
background and contains the lpr gene in homozygosity
leading to deficiency of the apoptosis-promoting Fas
(CD95) protein [11,12].
Crry is a widely distributed membrane-bound intrinsic
complement inhibitor [14,15]. It has cofactor activity for the
factor I-mediated cleavage of C3b and can cleave mouse C4b
in the presence of factor I [16]. Crry exhibits decay-acceler-
ating activity for both the classical and alternative pathways
and therefore is a potent homologous mouse complement
inhibitor. Crry-Ig is a chimeric form of Crry in which the non-
complement fixingmouse IgG1 Fc region was bound to the to
the functional domain of mouse Crry. The presence of Ig
prolongs the half-life making this a potent in vivo comple-
ment inhibitor. In this study we examined the effect of
complement inhibition with Crry-Ig [13] in MRL/lpr mice.
Two major findings were that complement activation led to
inflammation and a breach in the integrity of the blood–brain
barrier, which, in turn, led to heightened expression of AQ4 at
both the mRNA and protein level. These alterations were
restored to normal by complement inhibition.2. Materials and methods
2.1. Mice
Male MRL/lpr mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Age-matched unmanipulated
MRL/+ mice were studied in parallel. Here we studied 9
mice that had been injected intraperitoneally with 3-mg
Crry-Ig every other day [13] and 10 controls that received
saline at the same schedule from 12 to 24 weeks of age, at
which age they were sacrificed. An additional control group
of MRL/lpr mice was treated with normal mouse IgG
purified from normal mouse plasma by protein G chroma-
tography (Amersham-Pharmacia-Biotech, Uppsala, Swe-
den) instead of Crry-Ig. All work with mice was approved
by the University of Chicago Animal Care and Use Com-
mittee and was performed in accord with the NIH Guide for
the Care and Use of Laboratory Animals.
2.2. Measurements from tissue
Brains were isolated from animals sacrificed at 24 weeks
of age. Cerebellum and brain stem were discarded. The
anterior region of the cerebral cortex was snap frozen for
immunofluorescence (IF) microscopy, and the rest was
processed for RNA isolation.2.3. Tissue processing
Cryostat sections (4 Am) were processed for direct IF
microscopy using FITC- or TRITC-conjugated mouse IgG
(Cappel Laboratories, Durham, NC) antibody and indirect
IF with rat AQ4 antibody (Chemicon International, Teme-
cula, CA) followed by FITC-conjugated rabbit anti-rat IgG.
They were scored from 0.5 to 4 where 0.5 was negligible
staining and 4 very intense staining. Anti-mouse C1q
antibody was a kind gift from Dr Andrea Tenner (University
of California, Irvine). C1q was detected using FITC-labeled
anti-rabbit IgG.
2.4. DNA microarray analysis
RNA was isolated from the brains of 24-week-old MRL/
lpr mice, with and without Crry-Ig treatment, along with the
MRL/+ strain control using TRIzol reagent (Life Technol-
ogies, Grand Island, NY). The integrity of all RNA was
assessed by an Agilent Technologies 2100 Bioanalyzer
(Palo Alto, CA) and determined to be of excellent quality.
Five-microgram RNA was used as the template for the first
strand cDNA synthesis in a reaction primed with oligo(dT)
containing a T7 RNA polymerase promoter sequence. The
second cDNA strand was synthesized using E. coli DNA
polymerase 1 and ligase and was then used as template to
make biotinylated RNA probe by in vitro transcription. The
RNA probes were hybridized to MG-U74Av2 arrays (Affy-
metrix, Santa Clara, CA) according to the manufacturer’s
instructions. The hybridized arrays were scanned using a
Genearray Scanner (Agilent Technologies).
Data mining was done using both Affymetrix and Gene-
Spring software (Silicon Genetics, CA). For Affymetrix
software, global scaling was done to a target intensity of
500. Single array analysis was done to ascertain that the
arrays were of good and comparable quality. The parameters
included expression of glyceraldehyde phosphate dehydro-
genase (GAPDH) and its 3V/5Vsignal ratio, hybridization
efficiency using the ratio of the expression of the spiked
bacterial genes bioB, bioC, bioD and cre as well as the scaling
factors. Comparative analysis was done using the statistical
algorithms of MAS v.5.0. Standard GeneSpring analysis
involved importing Affymetrix signal data, which were then
normalized per chip and then per gene such that the median
value of each gene was 1.0. Restrictions were done to
eliminate genes scored as absent and to select for genes that
showed at least 1.3-fold increase in saline-treated MRL/lpr
brains compared to those from MRL/+ control mice.
2.5. Quantitative RT-PCR in lupus mice
To remove all traces of genomic DNA from brain RNA
isolated using TriZol reagent, samples were treated with
Rnase-free RQ1 DNase (1 U/4 Ag RNA; Promega, Madison,
WI) in 10-Al reaction buffer (final concentration, 40 mM
Tris–HCl, 10 mMMgSO4, and 1 mM CaCl2, pH 8) at 37 jC
hysica Acta 1639 (2003) 169–176
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EGTA (pH 8) to stop the reaction and incubation at 65 jC
for 10 min to inactivate DNase. cDNA was generated from
RNA using random hexamers as primers with the Super-
Script first-strand synthesis kit (Life Technologies), accord-
ing to the manufacturer’s instructions. Real-time PCR was
performed using a Smart Cycler (Cepheid, Sunnyvale, CA).
The probes were labeled at the 5Vend with the reporter dye
molecule FAM (6-carboxyfluorescein; emission max 518Fig. 2. C1q expression is colocalized with IgG in lupus brains. IF using
TRITC-labeled antibody for IgG staining (A) and FITC-labeled antibody
for C1q staining (B) clearly superimpose on one another (C) indicating that
the IgG colocalizes with immune complexes in lupus brain.
Fig. 1. Complement-dependent compromise of the blood–brain barrier in
murine lupus. Perivascular IgG (shown by arrows) staining seen in brains of
MRL/lpr mice was prevented by complement inhibition. MRL/+ (A), MRL/
lpr mice treated with saline (B) or Crry-Ig (C).nm) and at the 3Vend with the quencher dye molecule
TAMRA (6-carboxytetramethyl-rhodamine; emission max
582 nm). Each reaction was conducted in a total volume of
25 Al with 1-Al TaqMan Master Mix (PE Applied Biosys-
tems, Foster City, CA), 3-Al sample or standard cDNA,
primers at 200 nM each, and probe at 100 nM. PCR was
conducted with a hot start at 95 jC (5 min), followed by 45
cycles of 95 jC for 15 s and 60 jC for 30 s. For each
Fig. 3. AQ4 gene expression up-regulated in brains of MRL/lpr mice is
restored by complement inhibition. Shown is expression of AQ4 from two
separate probe sets on Affymetrix MG-U74Av2 arrays (Probe 1, ID
102703_s_at and Probe 2, ID 102704_at) as analyzed by GeneSpring
software in MRL/+ mice or MRL/lpr mice treated with either saline or Crry-
Ig from 12 to 24 weeks of age. Each point is the average of two values.
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threshold signal (Ct) was recorded. Using a standard curve
generated from serial dilutions of brain cDNA, the ratio of
AQ4 expression relative to GAPDH expression was calcu-Table 1
Serial order Probe position Probe sequence (5V–3V)
Probes from target sequence U48398 (antisense)
1 733 TCCGTTGCAATTGGACATT
2 756 TGCAATCAATTATACTGGA
3 779 GCATGAATCCAGCTCGAT
4 810 AGTTATCATGGGAAACTG
5 830 CAAACCACTGGATATATTG
6 850 GTTGGACCAATCATGGGC
7 885 CCTTTATGAGTATGTCTTC
8 902 TCTGTCCTGATGTGGAGC
9 912 TGTGGAGCTCAAACGTCG
10 992 ACAACCGGAGCCAAGTGG
11 993 CAACCGGAGCCAAGTGGA
12 1018 GACTTGATCCTGAAGCCC
13 1110 TTCCGTATGACTAGAGGA
14 1137 AGGCAGAAGAGACTCCCT
15 1202 TAAATTAGACACTTGCGG
16 1312 CCCTCAGAATCCAAGAAC
Probes from target sequence U88623 (antisense)
1 1257 GAATGTATCCCCAAAGCA
2 1265 CCCCAAAGCAACTATGCA
3 1266 CCCAAAGCAACTATGCAA
4 1277 TATGCAACTAGTGTATTGG
5 1286 AGTGTATTGGCTTCCCTTT
6 1317 AAATTATGAACCAAGATC
7 1323 TGAACCAAGATCTGGTCA
8 1333 TCTGGTCAAGTTTTGCCG
9 1334 CTGGTCAAGTTTTGCCGT
11 1357 GCATATGGACACCTCTGTG
12 1367 ACCTCTGTGAGGAAGCTG
13 1380 AGCTGGCATTGTCCATCG
15 1438 AAATGCAGTATGTCACAG
16 1449 GTCACAGAATCATGTGCAlated for each experimental animal. This was a suitable
control (i.e., ‘‘housekeeping’’ gene) as shown by both
Affymetrix and GeneSpring data analysis, in which GAPDH
gene expression was unchanged among all experimental
animals. Primers synthesized by Integrated DNA Technol-
ogies (Coralville, IA) and probe by Synthegen (Houston,
TX) for GAPDH were:
forward primer: 5V-GGCAAATTCAACGGCACAGT-3V;
reverse primer: 5V-AGATGGTGATGGGCTTCCC-3V;
probe: 5V-AAGGCCGAGAATGGGAAGCTTGTCATC-
3V;
The sequences of primers and probe for AQ4 synthe-
sized by Operon technologies (Almaeda, CA) as well as
the sequence position in U48398 provided in parentheses
were:
forward primer: 5V-AGGTGCCCTTTATGAGTATG-3V
(738–757)
reverse primer: 5V-CTTCCCTTCTTCTCTTCTCC-3V
(944–925)
probe: 5V-CTGTCCTGATGTGGAGCTCA-3V(762–781)Position in gene
mMIWC2, U48398
Position in gene
AQ4, U88623
TGTTTG 592–616, 640–664
GCCAGC 615–639, 663–687
CTTTTGG 638–663, 686–710
GGCAAAC 669–693, 717–741
GGTTGG 689–713, 737–761
GCTGTGC 709–733, 757–781
TGTCCT 744–768, 792–816
TCAAACG 761–785, 809–833
CCTTAAG 771–795, 819–843
AGACGGA 851–875, 899–923
GACGGAA 852–876, 900–924
GGAGTGG 877–901, 925–949
CAGCACT 969–993, 1017–1041
AGACCTG 996–1020, 1044–1068
GTTTCTT 1061–1085, 1111–1135
CCATAGG 1171–1195, 1613–1637
ACTATGC 1245–1269
ACTAGTG 1321–1345
CTAGTGT 1254–1278
CTTCCC 1265–1289
CATTAA 1274–1298
TGGTCAA 1305–1329
AGTTTTG 1311–1335
TGCAGAG 1321–1345
GCAGAGC 1331–1355
AGGAAG 1345–1369
GCATTGT 1355–1379
TCTTGAC 1387–1411
AATCATG 1426–1450
TTCAGGA 1437–1461
J.J. Alexander et al. / Biochimica et Biophysica Acta 1639 (2003) 169–176 1732.6. Statistics
Statistical analyses were performedwithMinitab Software
(College Park, MD, USA). Data are expressed as meanF
S.E. unless noted otherwise and statistical significance
was determined by one-way analysis of variance (ANOVA).
P values < 0.05 were considered statistically significant.3. Results
3.1. The blood–brain barrier is compromised in lupus
brains
Perivascular staining of IgG was seen by IF microscopy in
the thalamus of MRL/lpr mice given saline (Fig. 1B),
consistent with a compromise in the integrity of the blood–
brain barrier as compared to the MRL/+ controls (Fig. 1A).
Treatment of MRL/lpr mice with Crry-Ig considerably re-
duced brain perivascular IgG staining (Fig. 1C), indicating
that complement activation was responsible for the breach
in integrity of the blood–brain barrier. MRL/lpr mice
treated with normal IgG showed equivalent IgG staining
compared to mice treated with saline (not shown). C1q
staining was similarly increased, colocalizing with the
IgG, indicating these were immune complexes (Fig. 2).
3.2. Microarray studies identify complement-dependent
alterations in AQ4 expression
Initial studies were done to examine global gene expres-
sion in brains of lupus mice as well as to examine which of
these might be affected by complement inhibition. Two 24-
week-old mice from each of the three conditions were
studied, MRL/lpr mice treated with saline or Crry-Ig andFig. 5. Complement inhibition with Crry-Ig decreases AQ4 expression in
lupus brains. Representative IF staining for AQ4 in cortices of MRL/+ mice
(A) or MRL/lpr mice treated with either saline (B) or Crry-Ig (C) from 12 to
24 weeks of age. Arrowheads indicate staining around vessels and
capillaries while the arrow shows accumulation in glial end feet.
Fig. 4. Validation of microarray data by real-time PCR. RNA of mouse
brains was subjected to real-time PCR with AQ4 gene-specific primers and
probe as described in Section 2. Data are presented as AQ4 expression
relative to GADPH. Each point represents data from individual MRL/+
mice and MRL/lpr mice treated with either saline or Crry-Ig from 12 to 24
weeks of age.unmanipulated MRL/+ mice. RNA from individual mouse
brains was hybridized with separate arrays. Microarray
studies indicated that AQ4 gene expression was increased
in brains of MRL/lpr mice as compared to the MRL/+ strain
control (Fig. 3). As there are two AQ4 probe sets on the
MG-U74Av2 array (Table 1), data using each probe set is
given separately. As can be seen in Fig. 2, AQ4 expression
was increased by over twofold using both probes, compar-
ing MRL/lpr mice treated with saline to MRL/+ mice.
Treatment with Crry-Ig completely prevented this increase
Fig. 6. AQ4 expression is up-regulated both at the mRNA and protein level
in MRL/lpr mice which is prevented by complement inhibition with Crry-
Ig. RNAwas assessed by real-time PCR and protein expression determined
by IF for AQ4 in brains of MRL/+ mice or MRL/lpr mice treated with
either saline or Crry-Ig from 12 to 24 weeks of age. The real-time PCR
values have been multiplied by a factor of 3 to allow them to be compared
with IF results.
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remained unaltered in all three conditions with intensities
of 1.18, 0.94 and 1.01, respectively.
3.3. Complement inhibition restores up-regulated AQ4
expression to normal in lupus brains
Due to the conservative use of arrays and therefore the
small number of animals that were analyzed, we substanti-
ated the microarray data with real-time PCR analysis. As in
Fig. 4 showing data from individual animals, AQ4 expres-
sion was up-regulated in MRL/lpr mice (0.98F 0.38) com-
pared to their controls (0.30F 0.15) and this increase was
prevented with Crry-Ig treatment (0.20F 0.11) (P < 0.01 by
analysis of variance). These results substantiated the array
data and suggest that complement activation leads to up-
regulated AQ4 expression in lupus brains.
The expression of AQ4 protein was significantly in-
creased in MRL/lpr mice (Fig. 5B) as compared to the
control MRL/+ strain (Fig. 5A) while complement inhibi-
tion with Crry-Ig prevented this increase (Fig. 5C). The
staining was seen predominantly around the vessels (arrow-
head) and at accumulations of astrocytic end feet (arrow) in
the cortex. These results indicate that AQ4 expression is
greatly enhanced in lupus mice both at the transcriptional
level and at the protein level.
As shown in Fig. 6, there was a close parallel between
AQ4 mRNA and protein expression. AQ4 expression was
increased in MRL/lpr mice relative to MRL/+ controls, and
complement inhibition with Crry-Ig fully prevented this
increase.4. Discussion
SLE is a multiorgan disease characterized by alterations
in the regulation of both cellular and humoral immuneresponses. The MRL/lpr mouse is a murine model that
has the right genetic background coupled with Fas deficien-
cy that results in the expression of disease manifestations
similar to human SLE. Disease develops gradually during
life beginning at 8 weeks of age when there are elevated
levels of serum IgM. By 12 to 16 weeks of age, these mice
begin to produce autoantibodies. Finally, by 24 weeks, they
develop full-blown disease with proliferative immune com-
plex-mediated glomerulonephritis, vasculitis, arthritis, and
massive lymphadenopathy [17]. In this study we examined
genes that may be relevant in lupus cerebritis by comparing
gene expression in MRL/lpr to control MRL/+ brains.
Further, we determined the role of complement inhibition
in these animals.
Consistent with previous studies [18], we found perivas-
cular leakage of IgG and C1q presumably reflective of intact
immune complexes in MRL/lpr mice while the congenic
MRL/+ mice had none. Such IgG deposition seen in the
brains of lupus mice is analogous to the IgG deposits seen in
the choroid plexus of patients with SLE [19]. The presence
of immune complexes can be taken as evidence that the
blood–brain barrier is compromised in lupus, and this was
completely prevented by treatment with Crry-Ig. It seems
likely that deposition of immune complexes leads to com-
plement-dependent inflammation in the brain vessels of
MRL/lpr mice, and this is prevented through complement
inhibition.
Intra- and extracellular water exchange occurs by water
channels within the brain that appear to contribute to
excessive water accumulation in different pathological con-
ditions [20–22]. Previous immunohistochemical studies
have shown that in rats, AQ4 is the most important water
channel protein, and is localized on ependymal cells and
glial membranes that line blood vessels and ventricles in the
brain at the interface of brain, blood and CSF [23–26]. AQ4
was shown to have the same pattern of mainly astrocytic
expression in the cerebellum as other areas of the brain. The
time course and pattern of AQ4 expression during develop-
ment suggest that it plays an important role in brain water
metabolism during the second week of development [27].
The strategic localization of AQ4 and its high water per-
meability [28] enable it to function as efficient water-
selective transporting protein necessary for health but de-
ranged in certain pathologic conditions. For instance, fol-
lowing permanent focal cerebral ischemia, an increase in
AQ4 mRNA expression paralleled edema formation [29].
Similarly, knocking out AQ4 expression significantly re-
duced brain edema formation and improved the neurological
outcome following permanent middle cerebral artery occlu-
sion in mice [30].
In our study, AQ4 was expressed in the brain cortex of
MRL/lpr mice around microvessels and at accumulations of
astrocytic end-feet. Both RNA and protein expression were
increased in the brains of lupus mice. This is a significant
finding in the pathology of CNS lupus as this AQ4 increase
could alter CSF synthesis and absorption, fluid transport
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regulation [31]. In humans, 50% of SLE patients that had
lesions by MRI had vasogenic edema that may cause
hypertensive encephalopathy [32]. These lesions may be
reversible and caused by edema around small vessels [33].
MRIs of lupus patients with acute diffuse neurologic man-
ifestations such as seizures, psychosis and coma demon-
strated a longer spin-spin relaxation time of the gray matter
suggestive of the presence of acute cerebral edema com-
pared to other SLE patients [31].
Various mouse strains that develop a lupus-like disease are
studied to obtain insight into the etiology and pathology of
SLE. These mouse models share many features of the human
disease, including glomerulonephritis and antibodies to DNA
and other autoantigens, but differ in that once initiated the
murine disease is progressive while human SLE is character-
ized by a fluctuating course of flares and remissions [33].
In CNS-SLE there was an increase of CSF index values
for C3 and C4, indicating an important role for the com-
plement cascade in this disease [34]. To study the effect of
complement inhibition on murine lupus cerebritis, we trea-
ted MRL/lpr mice with Crry-Ig from 12 weeks at the onset
of autoimmune disease to 24 weeks when they had full-
blown disease. This treatment completely prevented the
increase of AQ4 mRNA and protein expression in lupus
brains. Circumstantial evidence supporting our findings is
that systemic complement inhibition by treatment with
cobra venom factor after intracerebral hemorrhage was
shown to attenuate brain edema and a positive correlation
was demonstrated between AQ4 and brain edema in focal
ischemia [8,35].
Our study is novel in that we used the complement
inhibitor Crry-Ig, thereby allowing chronic complement
inhibition not possible to-date, which prevented the in-
creased expression of AQ4 at both transcriptional and
protein levels in brains of lupus mice. It seems likely that
the elevated AQ4 protein expression in lupus mice is of
pathologic relevance, though this will require future studies
to determine the role of cerebral edema and AQ4 in this
disease model. These results strongly suggest that comple-
ment may play a significant role in brain edema by regu-
lating AQ4 expression, which is relevant in diseases that
have inflammation and altered water regulation.Acknowledgements
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